BALTIMORE, MD--(Marketwired - Sep 12, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Plandaí Biotechnology, Inc. (PLPL) has made significant strides in recent months as it nears an inflection point, which will migrate the Company from the development phase to the product commercialization phase. For example, Plandaí Biotechnology, through its wholly owned subsidiary, has completed its state-of-the-art production facility in Mpumalanga, South Africa, in the heart of its tea estate that sits on 7500 acres of land.
To ensure that the products are highly bioavailable, the unique processing and extraction system requires that the Company use only live plant material. Since the Company uses only live plant material, processing commences within an hour of the harvest.
There are a number of advantages to farming the extracts in South Africa, including the size and quality of the fertile land, economic benefits, and access to a farming teams with over 100 years of experience in managing farms in Southern Africa. The tea plant farmed on the property, Camellia Sinensis, is an evergreen shrub or tree and can grow to heights of 30 feet, but for proper cultivation purposes is pruned to heights of 2-5 feet only. In addition, this site farms a whole fruit basket of produce which it can potentially use in its creation of highly bioavailable extracts, including macadamia nuts, citrus, avocado, and artemesia, on top of its high profile 800+ hectares of tea.
Going forward, the farming team will soon fertilize and then allow the tea bushes to reestablish the high levels of polyphenols, before commercial production commences. The pre-production phase includes running test batches through the system and comparing those results to the original product profiles in order to guarantee the consistency of product quality prior to the commencement of full-scale production.
Management anticipates that Phytofare™ Catechin Complex production will be ready by year-end with the exciting citrus-based Limonoid Glycoside Complex available in the summer of 2014. Thus, the turn of the year should be a major catalytic event for Plandaí Biotechnology and its shareholders.
Goldman Small Cap Research sponsored articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (